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Introduction
Application of  antibiotics in the treatment of  bacterial 
disease hasbeen a noticeable medical success in this 
century. However, gradual emergence and spread of  
antibiotic resistance among bacterial population due 
to wrong or excessive use of  antibiotics has led to the 
development of  public health problems.
Bacillus genus is made up of  Gram positive aerobic or 
facultative endospore forming rod shaped bacteria. 
Bacteria of  the genus Bacillus are known to produce 
natural products (1). They possess antagonistic 
activities against many bacterial and fungal pathogens 
and are often used as agents for the treatment and/or 
prevention of  different plant and animal infections.
 Their antimicrobial activities have mainly been attributed 
to the production of  antibiotic peptide derivatives as 
bacteriocins and bacteriocin-like inhibitory substance, 
lipopeptides, which have powerful surfactant like 
properties with numerous biotechnological applications 
including deemulsification, health care, and food 
industry (1) Bacillus spp. can produce antibiotics which 
are in peptid structure, such as  bacitracin, polymyxin, 
tyrosidin, grmysidin, subtilin and sirkulin. For this 
reason, they have an important role in drug industry. 
Their antimicrobial activities have mainly been attributed 
to the production of  antibiotic peptide derivatives and 
lipopeptides (1-3).
Coagulase- negative Staphylococcus (CNS) causes the 
vast majority of  post- operative endophtalmitis cases. 
Intraocular infections with S. aureus, enterococci, 
Bacillus or Gram negative species are often intractable. 
Because of  these, blindness or loss of  the eye itself  
is not uncommon (4,5).  Resistance to antibiotics in 
CNS is major concern. Penicillin resistance in CNS 
is very high (6,7).  Methicillin-resistant Staphylococcus 
species, especially S. aureus strains, appeared in the 
hospital environment and acquired resistance not only 
to ß-lactam antibiotics but also to flouroquinolones, 
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chloramphenicol, clindamycin, tetracycline, and 
aminoglycosides (8). Recently, a decrease in the 
susceptibility of  methicillin-resistant Staphylococcus 
species to vancomycin and teicoplanin has also been 
reported in several hospitals around the world  (9-10).
The need for antibiotics and antimicrobials continues 
to be a major challenge for the treatment of  infectious 
disease which affect millions of  people worldwide. 
Furthermore, antimicrobial resistance is a growing 
concern. Also, the number of  resistant bacteria and 
the geographic distribution of  these organisms are 
both rising. We will need new products against these 
organisms. Human eye-derived microorganisms might 
be a useful source of  natural products.
In this study, we screened Bacillus spp. strains, which 
were isolated from human eyes, for their antibacterial 
activity against human eye pathogens.
Material and methods
Bacterial cultures
Several Bacillus spp. were used as the producer strain. 
Strains of  Bacillus spp. which were isolated previously 
from healthy eyes and stored as pure state were chosen. 
The nutrient agar was used for maintenance of  the 
strain with 20% (v/v) glycerol at -86°C.
In this study, eye pathogens (Staphylococcus  aureus SDA 
40.2, SDA 48, Staphylococcus epidermidis KA 11.1, KA 14.1, 
KA 17.1, SDA 44,  Staphylococcus warneri PCA 9.5,  KA 
11.2, Staphylococcus hominis PCA 6.3,  PCA 9.2,  PCA 9.3, 
Staphylococcus lugdunensis PCA 7.2, KA 15.9, Micrococcus 
luteus PCA 7.1, Enterococcus faecalis PCA 39.1.1,  Bacillus 
cereus 13.2 PCA,  Listeria monocytogenes 47 PCA and Proteus 
mirabilis KA 44.1 )  were used as test bacteria.
Screening for antimicrobial activity by cross-streak method
In primary screening, all Bacillus spp. isolates were 
streaked as a straight line at the centre of  agar plates. 
These plates were incubated at 37oC for 24 hours. On 
the incubation, tested bacteria were inoculated using 
a single streak that was perpendicular to the Bacillus 
growth streaked at single straight line at the centre of  
the plate followed by incubation at 37oC for 24 hours. 
Inhibition zones formed were measured in millimeter 
(11).
Antimicrobial activity of  cell free supernatant by well diffusion 
method
To extract bioactive compound from culture supernatant 
during the growth cycle, 28 producer strains Bacillus were 
separately inoculated using 200 ml sterile nutrient broth 
(NB) and incubated on a shaker at 37°C overnight 120 
rpm for 48 hours.  Cells were collected from a 48 hours 
culture by centrifugation (6000 rpm for 20 min, at 4°C) 
and the supernatant recovered and passed through a 
0.22 μm filter.   
The determination of  the inhibitory effect of  cell free 
supernatant of  isolates on test bacteria was carried out 
according to the well diffusion method. Pre-poured 
agar media plates equilibrated were spread with 106 cfu/
ml of  respective test organism and allowed to dry. In 
the agar plates, wells of  6 mm diameter were cut using 
a cork borer. The wells were filled with 80 µl of  cell 
free culture supernatant and incubated overnight at 
37ºC. The plates were then examined for clear zones of  
inhibition surrounding each well and inhibition zones 
were measured. 
The test was duplicated for each Bacillus isolate.
Partial purification bioactive compound
The isolates were inoculated into flasks containing 100 
ml nutrient broth and incubated at 37oC in a shaker 
at 120 rpm for 48 hours. After growth, culture media 
were centrifuged at 6000 rpm for 20 min, at 4°C and 
the supernatant recovered and passed through a 0.22 
μm filter. Cell-free culture was extracted 3 times with 
an equal volume of  ethyl acetate according to the 
method of  Han et al. (12). Ethyl acetate was added 
to the supernatant in ratio of  1:1(v/v). The mixture 
was shaken vigorously for 10 min and separated. 
Subsequently, the ethyl acetate extract was pooled and 
evaporated to dryness under vacuum at 60oC for 20 min 
in water bath (13).
After extraction, bioactive compound, which were 
antibacterial activity, were chosen using disc diffusion 
methods. A 20-ml aliquot of  partial purification 
bioactive compound was applied to disks (6 mm) placed 
on agar plates previously inoculated with a suspension 
of  each eye pathogens. The plates were incubated at the 
37oC for 24 hours. The diameter of  inhibition zones 
was measured.
MIC test was applied to the partial purification bioactive 
compound, which had most antimicrobial activity. 
Therefore, Minimum inhibitory (MIC) values were 
determined using the method of  two fold serial dilution 
(14).
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Antibiotic Susceptibility Testing
Antimicrobial resistance patterns of  test bacteria were 
determined by the agar disk diffusion method. Disks 
containing the following antibacterial agents were used: 
gatifloxacin (5 µg), cefuroxime (30 µg), ceftazdime (30 
µg), vancomycin (30 µg), gentamicin (10 µg), amikacin 
(30 µg), ciprofloxacin (5 µg), lomefloxacin (10 µg), 
moxifloxacin (5 µg), methicillin (10 U). Characterization 
of  strains as sensitive, intermediate or resistant was 
based on the size of  the inhibition zones around each 
disk according to the National Committee for Clinical 
Laboratory Standards (CLSI) criteria (15).
Results 
Screening for antimicrobial activity using cross-streak method
Twenty eight strains of  Bacillus sp. which were isolated 
previously from healthy eyes were included in the 
study. These isolates were screened for antimicrobial 
activity against eye pathogens using cross-streak 
method. Therefore, it was noticed that 11 of  28 strains 
had antimicrobial activity against one or more eye 
pathogens. 
Antimicrobial activity of  cell free supernatant by well diffusion 
method
Cell free supernatant (CFS) of  culture of  11 isolates 
were screened for antimicrobial activity against eye 
pathogens. The antimicrobial spectrum of  cell free 
supernatant was given in Table 1. 
























































S. hominisPCA 9.2 12 10 12 14 14 12
S. hominisPCA 9.3
S. warneriPCA 9.5 10 12 10 10 12 12
B. cereus13.2 PCA 16
S. epidermidisKA 11.1 12 8
S. epidermidisKA 14. 1 14 10
S. lugdunensis KA 15.9 12
P. mirabilisKA 44.1 12 10 10 10 10 10
S. aureusSDA 40.2 12 12 12 14 14 12
S. epidermidisSDA 44 14 12 14 14 14 14
From this screening, 7 Bacillus sp. showed antimicrobial 
activity against test bacteria. S. aureus SDA 48, S. 
epidermidis KA 17.1, S. warneri KA 11.2, S.  hominis PCA 
6.3, S. lugdunensis PCA 7.2, M. luteus PCA 7.1, E. faecalis 
PCA 39.1.1, B. cereus 13.2 PCA, L.monocytogenes 47 PCA 
were found as resistant to all the cell free supernatant. 
While, S. hominis PCA 9.2, S. warneri PCA 9.5, P. 
mirabilis KA 44.1,  S. aureus SDA 40.2 and S. epidermidis 
SDA 44 were found the most sensitive to the cell free 
supernatant. 
Antimicrobial activity of  partial purification bioactive 
compound
Partial purification of  bioactive compound from liquid 
culture of  Bacillus spp. was carried out. The antimicrobial 
spectrum of  partial purification supernatant is given in 
Table 2. Nevertheless, Inhibitory activity  observed on 
S. hominis PCA 9.2, S. aureus SDA 40.2, S. warneri PCA 
9.5, S. warneri KA 11.2, B. cereus 13.2 PCA, L.monocytogenes 
47 PCA, S.epidermidis KA 11.1, KA 14.1, KA 17.1,  S. 
lugdunensis KA 15.9 , M.luteus PCA  7.1 and E. faecalis 
PCA 39. 1.1  were not  inhibited.
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B. pumilusPCA 4.2 nt nt 10 10 10 12 10 10
B. pumilusPCA 9.4 nt nt 10 12 12 10 10 10 12 10 10
B. subtilis  PCA 11.2 10 nt nt 14 12 12 10 10 12 10 10 12 10 12 12
B. cereusPCA 15.3 nt nt 10 10 10 10
B. mojavensis PCA 24.1 nt nt 10 14 10 10 12 10
B. mojavensis 3 PCA nt nt 10 14 12 10 14 14 14 10 12 10 10
B. mojavensis 3M17 nt nt 12 12 14 10 10 10 10 10 10
B. mojavensis KA 39.3 nt nt 10 10 12 10 10
B. mojavensis 25-2-C2PX nt nt 10 12 14 10 10 10
nt, not tested
The MICs were evaluated for all partial purification of  
bioactive compound MIC. B. mojavensis 3 PCA in Partial 
purification of  bioactive compound showed the lowest 
MIC value. Although, there is interesting selectivity with 
good activity against MRSA S. aureus SDA 40.2 and S. 
epidermidis SDA 44 (4.31µg/ml), yet no activity against 
S.hominis PCA 9.2, B. cereus 13.2 PCA, L. monocytogenes 47 
PCA and S. aureus SDA 40.2. While, these bacteria may 
need more substance of  higher concentration. It was 
noticed that, MIC values of  the other pathogens were 
found 8.63µg/ml. Notwithstanding, as we could not get 
enough substance from other strains so we could not 
find MIC values. 
Antibiotic Susceptibility tested eye pathogens
Antibiotic resistance patterns of  the eye pathogens 
were summarized in Table 3. Two S. aureus, five CNS 
cultures showed methicillin resistance. Three culture 
CNS showed no drug resistance. 
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E. faecalisPCA 39. 
1.1 R R R 21 14 14 17 23 R 11
S. aureus SDA 48 14 R 19 23 20 R 7 R 26 R
S. aureus SDA 40.2 16 R 20 23 21 24 R 32 22 40
S. epidermidis SDA 
44 30 16 22 24 25 14 19 21 20 26
S. epidermidis KA 
17.1 R R R R 30 R 17 11 R 20
S. epidermidis KA 
14.1 30 R 20 R 26 21 23 26 R 23
S. epidermidis KA 
11.1 16 R 23 35 14 14 R 32 35 26
S. warneri PCA 9.5 R R R 30 19 20 23 30 21 27
S. warneriKA 11.2 35 25 25 27 27 24 22 31 26 21
S. hominis PCA 9.3 24 21 21 30 20 27 15 11 36 21
S. hominis PCA 9.2 42 30 34 30 32 40 21 37 34 40
S. hominis PCA 6.3 46 30 26 37 44 33 11 40 43 36
S. lugdunensis KA 
15.9 51 26 21 40 31 30 30 46 56 43
S. lugdunensis 4PCA 
7.2 11 R R 30 22 20 19 37 40 32
P. mirabilisKA 44.1 26 16 19 33 21 14 20 52 R 19
M. luteus PCA 7.1 40 12 26 26 32 21 21 31 22 27
B. cereus13.2 PCA R R R S 21 26 20 35 40 42
L.monocytogenes47 
PCA R R 12 30 21 26 21 40 26 26
Discussion
There are many species of  the genus Bacillus which 
can produce a wide variety of    antibiotics including 
bacitracin, polymyxin, colistin etc. On this note, several 
bacitracins were characterized; the bacitracin A is the 
commercial product (16).
The present research work was carried out using 
bioactive metabolites obtained from B. pumilus PCA 
4.2, PCA 9.4, B. subtilis  PCA 11.2, B. cereusPCA 15.3, 
B. mojavensis PCA 24.1, 3PCA, 3M17,  KA39.3  and 25-
2-C2PX.
The antibacterial activity of  the Bacillus spp. was tested 
against different eye pathogens. These eye pathogens 
were Methicillin resistant S. aureus SDA 40.2 and S. 
aureus SDA 48, S. epidermidis KA 11.1, S. epidermidis 
KA 14.1, S. epidermidis KA 17.1, S. warneri PCA 9.5, S. 
lugdunensis PCA 7.2 while, other eye pathogens were 
S. epidermidis SDA 44, S. warneri KA 11.2 S.  hominis 
PCA 6.3, S.  hominis PCA 9.2,  S.  hominis PCA 9.3, S. 
lugdunensis KA 15.9, M. luteus PCA 7.1, E. faecalis PCA 
39.1.1, B. cereus 13.2 PCA, L.monocytogenes47 PCA and P. 
mirabilis KA 44.1.  
Antimicrobial activity of  Bacillus spp. was noticed 
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from the work of  other researchers. Oscariz and 
Pisabarro (17) isolated and identified cerein 7, which 
was a bacteriocin produced by B. cereus Bc7 and inhibits 
growth of  Listeria spp. and other gram-positive bacteria. 
Bizani and Brandelli (18) isolated and identified cerein 
8A. That was a bacteriocin produced by B. cereus that 
inhibits growth of  Listeria spp. and M. luteus. Antibiotic 
production abilities of  B. subtilis, B. polymyxa and B. 
brevis, B. licheniformis, B. cereus were showed by Yılmaz 
and Beyatlı (19). In our study, antimicrobial activity was 
noticed in 1 strain of  B. subtilis and 1 strain of  B.cereus. 
B.cereus partial purification bioactive compound had been 
effective over S.hominis PCA 9.2, S. lugdunensis KA 15.9, 
L.monocytogenes 47 PCA and P. mirabilis KA 44.1. Also, B. 
subtilis, showed effectiveness over test bacteria except 
S.hominis PCA 9.3, S. epidermidis KA 17.1 and E. faecalis 
PCA 39.1.1.   Bacillus cereus produces several bacteriocin-
like inhibitory substances (1). Tabarez et al. (20) reported 
an antimicrobial activity of  substances produced by 
B.subtilis(soil isolate) against multidrug-resistant bacterial 
pathogen including methicillin-resistant S. aureus. El-
Bana et al., (21) reported preliminary antimicrobial 
activity of  substances produced by Bacillus subtilis 
NB-6 (air flora isolate), Bacillus megaterium NB-3 (air 
flora isolate) against a number of  methicillin-resistant 
Staphylococcus aureus (MRSA). Effective antimicrobial 
compounds with a broad spectrum of  activity against 
Gram positive and Gram-negative bacteria, and also 
against methicillin- resistant Staphylococcus clinical 
isolates (S. hominis, S. epidermidis, S. aureus, S. haemolyticus, 
S. warneri, S. cohinii and S. scuiri), were secreted by B. 
subtilis B38 strain into the culture medium (9). In this 
study, any of  the biological active matters, which were 
tested, were not effected over E. faecalis PCA 39.1.1 and 
S. epidermidis KA 17.1. Accordingly, these pathogens 
showed resistance to antibiotics which are commonly 
used.
In this study, B. pumilus PCA 4.2 and B. pumilus PCA 
9.4 showed antibacterial activity  against methicillin 
resistant S. epidermidis  KA 11.1 and  S. epidermidis 14.1. 
Moreover, in one of  the studies, B.pumilus showed 
surfactin production (22) and in another study B.subtilis 
and B.pumilus showed antibacterial activity against many 
Gram negative and Gram positive bacteria (23). Hence, 
B. pumilus produces plasmid-encoded peptide pumilicins 
(1). However, pumilicins show remarkable antibacterial 
activity against MRSA, vancomycin-resistant E. faecalis 
(VRE) and several Gram-positive test bacteria (24).  This 
not with standing, Awais et al. (25) studied inhibitory 
effects of  a Bacillus sp. isolate on 2 pathogenic strains 
of  M.luteus and S.aureus. In addition, Hasan et al. (26) 
have reported a compound produced by B. pumilus that 
inhibits M.luteus and S. aureus. Ma et al. (27) isolated three 
lipopeptids from B. mojavensis B0621A. One of  these 
lipopeptids, which was identified as iturinic lipopeptid, 
showed bioactivity. This was named as mojavensis A. 
We found antimicrobial activity in 4 of  5 strains of  B. 
mojavensis. Similar results were found by Kim et al., (28). 
Reportedly, mersacidin  produced by Bacillus sp. HIL 
Y-85, 54728 inhibited the growth and colonization of  
methicillin resistant S.aureus (29).
Therefore, the identity of  the bioactive compound 
produced by the Bacillus sp. is still unknown. Thus, 
further analysis by protein electrophoresis and MS/MS 
mass spectrometry may help to reveal the identity of  
the protein.
Conclusions
Bacillus spp. has been considered as a potential agent 
to control against eye pathogens. The bacteriocin or 
bacteriocin-like inhibitory substance, lipopeptides 
produced by the strain B. mojavensis 3PCA and B.subtilis 
PCA 11.2 may represent an antimicrobial substance with 
potential application in the prevention and treatment 
of  eye infection. Although some bacteriocins from 
Bacillus present a narrow antimicrobial spectrum, the 
antibacterial activity of  B. mojavensis 3PCA and B.subtilis 
PCA 11.2 were comparable to broad-range bioactive 
compound associated with Bacillus spp.
In this study, we have described the antimicrobial 
activity of  substances produced by B.subtilis, B. pumulis 
and B. mojavensis against several methicillin-resistant S. 
aureus, S. epidermis and S. warneri strain which may serve 
as a promising development for new drugs against 
microbial pathogens. The inhibition of  bacterial strains 
(methicillin-resistant S. aureus S. epidermidis and S. 
warneri) using B. subtilis PCA 11.2 and  B. mojavensis 3 
PCA  may represent an antimicrobial substance with 
potential application in the prevention and treatment 
of  eye infection and may be proposed as an alternative 
strategy for infection control.
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